Tolerance and Growth Outcomes in Children Diagnosed With Cow's Milk Protein Allergy and Prescribed an Extensively Hydrolyzed Casein Formula (Damira 2000©) in Spain

Inclusion Criteria: 1. Patients with a diagnosis of allergy to cow's milk protein (CMPA): either confirmed through a placebo-controlled food challenge (DBPCFC) or highly suspected based on specific suggestive symptoms; 2. Patients under the age of 1 year at the time of cow's milk protein allergy diagnosis. 3. Patients taken Damira 2000 for at least 4 months at the time of data extraction. 4. Patients with information available on child growth (weight and height) and the following anthropometric indices at diagnosis and for at least 2 follow-up visits after first hospital visit/4 months\*: Z-scores for weight-for-age (WAZ), height-for-age (HAZ), weight-for-height (WHZ) and body mass index (BMI)-for-age (BAZ). Exclusion Criteria: 1. Patients who used other infant formulae or breast milk in addition to the study product of interest during the retrospective study period. 2. Premature children with a low birth-weight (\<2.5 kg). 3. Patients diagnosed with a metabolic condition that impacts development and growth. 4. Patients diagnosed with a congenital condition and/or with prior or current disease that in the opinion of the investigator could potentially interfere with the aim of the study.